Leadership

Leadership


Asclepius Life Sciences Fund, L.P. is uniquely positioned to participate in the rapidly evolving life sciences landscape.

Our nationally recognized, veteran team has extensive operational expertise in life sciences and investment expertise in maximizing long-term risk-adjusted returns.  Our team’s strategic and operational experience covers most therapeutic classes of life sciences including strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management.  Management is aligned with shareholder interests in creating fundamental value via ownership and performance-based compensation.


Steve Glover

Co-Founder & Managing Principal

Steve Glover is the Co-Founder and Managing Principal for Asclepius Life Sciences Fund, L.P.

He has extensive experience and success in biopharmaceutical company turnarounds and growing top line revenues, with a focus on business strategy.  His experience spans Fortune 100, start up and entrepreneurial environments. He has extensive success in turnarounds and growing the top line, with a focus on business strategy, corporate development, product development, commercialization and business optimization. His transaction experience covers over 25 transactions totaling over $10 billion. His strategic and operational experience, which covers most therapeutic classes of biopharmaceuticals, includes strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management.

Currently Mr. Glover is Co-founder, President and CEO of Variant Pharmaceuticals. Variant is an emerging specialty pharmaceutical company leveraging advanced proprietary technologies to develop two best-in-class drug therapies for patients with rare diseases or other conditions with limited or sub-optimal treatment options. Before founding Variant, Mr. Glover was Co-founder and Chief Business Officer of Coherus BioSciences. Coherus BioSciences is a late-stage biologics platform-company focused on delivering high-quality biosimilar therapeutics. Coherus (CHRS) became a publicly traded company in November of 2014.

Prior to co-founding Coherus, he was the President of Insmed Therapeutic Proteins as well as EVP and Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As EVP and Chief Business Officer he led Insmed’s strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. He earlier held multiple executive roles in sales, marketing and operational roles at Roche Laboratories, Amgen Inc. and IMS Health. Currently Mr. Glover serves on the Board of Directors of Variant Pharmaceuticals, Two-B Pharma and InflamaCore. Additionally Mr. Glover serves as an Executive in Residence at the University of Miami U Innovation Life Sciences Office. Mr. Glover received his B.S. in Marketing from Illinois State University in 1982.


Dr. Steven Gerst

Co-Founder & Principal

Dr. Steven Gerst is the Co-Founder and Principal of Asclepius Life Sciences Fund L.P.  Dr. Gerst holds Series 7  and Series 65 Securities Licenses.  He focuses on biopharma and medical technology.

Dr. Gerst is a graduate of the Columbia University College of Physicians and Surgeons (M.D.) and is an Aresty Scholar of the Wharton School of Business at the University of Pennsylvania.  He is a graduate of Columbia College (B.A.), Columbia School of Public Health – Health Administration (M.P.H.) and the Goizuetta School of Business at Emory University (M.B.A.).  Dr. Gerst is Board Certified in Medical Management and is Diplomat in the American College of Healthcare Executives.

Dr. Gerst holds certificates of completion in additional course work from Harvard Business School, Harvard Law School, Harvard School of Public Health and the Wharton School of Business at the University of Pennsylvania.  He is on the Faculty at the University of Miami School of Health Sciences and Nursing (on-line program) and at the Miller School of Medicine working for the Vice Provost in the Office of the Chief Innovation Officer as an “Entrepreneur– in-Residence.”

Dr. Gerst is formerly Senior Consultant and Regional Medical Director for what is now PricewaterhouseCoopers, LLP. He was President of Columbia/HCA’s PPO division nationally under Florida’s current Governor, Rick Scott, and Vice President of the corporation (NYSE:HCA). Prior to that, he was Assistant Vice President of Crawford & Company (Atlanta; NYSE:CRDA and CRDB) the world’s largest independent claims management company, with more than 700 offices in 70 countries. At Crawford & Company, he built the first nationwide PPO for AIG, Boeing and other Crawford clients with 1,200 hospitals and 120,000 physicians.

He began his career with what is now Premier, Inc. (NASDAQ: PINC) serving 3,750 member and owner hospitals where he built HMOs, PPOs and ran the Utilization Management consulting division. Premier is the nation’s largest Health Care Group Purchasing Organization. He is also Dean Emeritus of the Masters of Science Program in Applied Health Informatics at Bryan University (Los Angeles, Sacramento, Toronto and Phoenix) where he serves on the Board of Advisors and has taught on the faculty (http://bryanuniversity.edu/advisory-board-members/?). He is heavily involved in the medical device industry, remote patient monitoring and telemedicine and is currently working on projects with Intel, AT&T, Citrix, Cognizant, ADT, Qualcomm, Epic and Cerner developing connected health platforms for large integrated delivery systems and IPA groups.


Steve Mackey

Managing Director

Asclepius Master Fund, LTD.

Steve Mackey is Managing Director of Asclepius Master Fund, LTD.  He represents the Fund on a global basis.

Mr. Mackey is a seasoned executive with over 30 years experience in global financial services as an executive, entrepreneur, and financial advisor. Mr. Mackey has  lived in four countries and managed, opened and acquired businesses in many more. He is currently the CEO and Founder of MLG Capital, a licensed securities firm in The Bahamas.

Prior to establishing his own securities firm in 2014, Mr. Mackey held various client facing and executive roles with three international banks. He began his financial services career with Royal Trust/RBC in Ottawa, and for the first 10 years held many progressively challenging client facing & sales management roles in Southern Ontario. In 1997, he was appointed Managing Director of RBC Global Private Banking in the Cayman Islands and director on various RBC subsidiaries in the Bahamas, Bermuda, and Barbados.

In 2001, Mr. Mackey was appointed General Manager of RBC Suisse in Geneva, Switzerland, with regional responsibility for Europe and the Middle East, with sales offices located in Dubai, Istanbul and Madrid. In 2005 he returned to Toronto with RBC as Managing Director to oversee the Caribbean & USA Global Private Banking businesses in the Americas region.

In 2006, Mr. Mackey joined EFG International as Regional CEO in The Bahamas and established the banks Private Banking operations in the Bahamas and the Cayman Islands, and acquired an investment management business in Canada.

In 2011, Mr. Mackey was recruited to be the Country CEO and Managing Director of Private Banking for Credit Suisse with a key focus on the Caribbean and LATAM markets.

Mr. Mackey graduated from the University of New Brunswick in 1986 with a Bachelor of Arts degree. He attended Queens University School of Business, Executive Finance program in 1999.  He received his Trust and Estate Practitioner (TEP) designation in 2000.  He completed all requisite Canadian Securities Institute courses to be a licensed Investment Advisor in Canada. Mr. Mackey was previously licensed in the Cayman Islands and has been licensed to advise and manage securities in the Bahamas since 2006.

 



| Accredited Investors

The information contained in this web site has been prepared solely for accredited investors. It is for informational purposes and is not an offer to sell or purchase or a solicitation of an offer to sell or purchase any interests or shares in any of the funds managed by Asclepius Investment Strategies, LLC Such offers are made only by way of a private offering memorandum delivered to qualified investors.

| Contact

ASCLEPIUS LIFE SCIENCES FUND, L.P.
641 Lexington Avenue, Suite 1337
New York, NY 10022
Phone: (212) 634-6440
Fax: (212) 634-6480